AC Immune S.A. (ACIU) Company Overview

What does AC Immune do?

AC Immune S.A. is a Swiss clinical-stage biopharmaceutical company focused on neurodegenerative diseases caused or influenced by misfolded proteins. It does not sell an approved medicine. Instead, it discovers therapeutic and diagnostic candidates, advances selected programs through clinical development, and shares development risk with large pharmaceutical partners. The company is listed on the Nasdaq Global Market under ACIU and reports under IFRS as a foreign private issuer through Form 20-F and Form 6-K filings.

Two technology platforms define the company

The scientific architecture is built around SupraAntigen and Morphomer. SupraAntigen is used to design biologic approaches, especially active immunotherapies intended to stimulate a patient’s immune system against pathological proteins. Morphomer is a small-molecule platform designed to generate brain-penetrant compounds and PET imaging agents that bind specific pathological protein conformations. The company’s official pipeline spans amyloid beta, phosphorylated Tau, alpha-synuclein, NLRP3 inflammasome biology, and diagnostic tracers.

Why precision prevention matters to the strategy

AC Immune’s strategic idea is to identify disease biology through biomarkers and intervene before irreversible neuronal loss becomes advanced. That is why several programs target prodromal or pre-symptomatic populations rather than only late-stage disease. This positioning matters commercially because successful prevention could require long treatment duration, good tolerability, convenient administration, and reliable biomarker selection. It also raises the clinical bar: trials must demonstrate that changes in antibodies, PET scans, cerebrospinal-fluid markers, or other biomarkers translate into meaningful patient outcomes.

How does AC Immune make money without approved products?

AC Immune monetizes research assets before commercialization through collaboration economics. Revenue is not driven by prescription volume, market share, or recurring product sales. It comes from upfront license consideration, development work performed for partners, option fees, milestone payments, grants, and potentially royalties if an approved product eventually reaches the market. The latest 2025 Form 20-F explicitly states that the company has never generated product-sales revenue.

Contract revenue is milestone-driven, not recurring

This model creates highly uneven reported revenue. FY2025 contract revenue was CHF 3.6 million, compared with CHF 27.3 million in FY2024 and CHF 14.8 million in FY2023. The difference does not mean underlying demand collapsed in the way it might for a commercial drug company. It reflects the timing of collaboration obligations and milestone recognition. Takeda’s $100 million upfront payment in May 2024 strengthened liquidity, but much of the accounting value is recognized over the period in which AC Immune completes development, CMC, and regulatory activities required by the agreement.

Deferred revenue shows work still owed to partners

At March 31, 2026, short- and long-term deferred contract revenue totaled CHF 84.9 million. This liability is economically important: AC Immune already received consideration but must still perform contractual obligations before recognizing the associated amount as revenue. A large deferred balance therefore supports cash resources while also representing future work, cost, and execution responsibility.

Which pipeline programs matter most?

ACI-7104 is the clearest wholly owned clinical catalyst

ACI-7104 is an anti-alpha-synuclein active immunotherapy in the Phase 2 VacSYn trial for early Parkinson’s disease. The December 2025 interim analysis covered 34 patients randomized 3:1 to treatment or placebo. AC Immune reported a 100% responder rate, serum and cerebrospinal-fluid antibody titers more than 500-fold above placebo at week 76, and directional stabilization across several disease-related biomarkers and motor assessments. The interim Phase 2 results remain exploratory because the study is small, but they made ACI-7104 the most important internally controlled clinical asset. Final week-104 Part 1 data are expected in H2 2026.

Partnered Alzheimer’s programs carry different option structures

ACI-24 is being tested in the ABATE Phase 1b/2 trial for prodromal Alzheimer’s disease and Down syndrome-related Alzheimer’s. The June 2026 update covered 74 patients across cohorts AD1-AD3 after 12 months. The candidate was generally safe and well tolerated, with no reported ARIA-E, and produced dose-responsive anti-amyloid antibodies; however, management concluded that immunogenicity should be strengthened for more effective plaque removal. The additional-adjuvant AD4 cohort starts with 36 patients and may expand the trial population to approximately 112. The ABATE update therefore contained both a favorable safety signal and a formulation challenge.

What turning points shaped AC Immune’s current strategy?

The company’s history is best understood as a sequence of platform validation, partnering, portfolio expansion, and renewed focus. Several early antibody partnerships generated capital and credibility, but later terminations also demonstrated that a biotech platform cannot rely indefinitely on legacy programs. The current model combines active immunotherapies for extracellular pathology with small molecules intended to reach intracellular disease mechanisms.

From platform creation to a focused precision-prevention portfolio

1. 2003
   AC Immune began operations in Lausanne, establishing the protein-misfolding focus that still defines its scientific identity.
2. 2006-2012
   Genentech collaborations around amyloid-beta and Tau antibodies validated the company’s science and produced early non-dilutive payments; both agreements later ended in 2024.
3. 2014
   Janssen licensed the anti-Tau active-immunotherapy program that became JNJ-2056, establishing a long-duration partnered development path.
4. 2016
   The Nasdaq IPO added access to public capital and broadened the shareholder base while diluting the pre-IPO controlling stakes.
5. 2018-2019
   The Lilly Morphomer Tau collaboration brought CHF 80.0M upfront and confirmed that the small-molecule platform could attract major-pharma economics.
6. 2021
   The $58.7M all-stock Affiris portfolio acquisition added the predecessor of ACI-7104 and made Parkinson’s disease a major strategic pillar.
7. 2024-2025
   The $100.0M Takeda agreement for ACI-24 strengthened liquidity, while the September 2025 operational review concentrated spending on Phase 2 immunotherapies and high-value intracellular programs.
8. 2026
   Lilly expanded the Tau collaboration, ACI-19764 entered Phase 1, and co-founder Andrea Pfeifer retired as CEO, creating a leadership transition during a catalyst-heavy year.

The September 2025 pipeline-focus initiative is especially relevant to current financial analysis. Headcount fell from 172 at December 2024 to 122 at December 2025, and Q1 2026 R&D expense declined by CHF 4.2 million year over year. The strategic trade-off is clear: concentrating capital can extend runway and improve decision quality, but it also increases dependence on fewer prioritized assets.

What do the latest financial results show?

Q1 2026 shows lower spending, not operating profitability

For the quarter ended March 31, 2026, revenue rose 13.0% to CHF 1.1 million from CHF 1.0 million, but revenue remained small relative to development expense. R&D fell 26.2% to CHF 11.7 million, G&A declined 6.1% to CHF 4.2 million, and total operating expense declined 21.9% to CHF 15.9 million. The operating loss improved to CHF 14.8 million from CHF 19.4 million, while net loss improved to CHF 14.8 million from CHF 19.0 million. The Q1 2026 reporting package attributes part of the R&D reduction to pipeline-focus savings and lower active-immunotherapy CMC spending.

Annual revenue history highlights the accounting volatility

The key financial signal is therefore expense velocity and milestone conversion, not a conventional revenue CAGR. AC Immune’s income statement can swing sharply when a contract is signed or a milestone is recognized, while the underlying research organization continues to consume cash.

How strong is the balance sheet and cash runway?

Cash resources are liquid, but the runway still depends on burn control

At March 31, 2026, cash and equivalents were CHF 19.2 million and short-term financial assets were CHF 55.6 million. Together they represented CHF 74.8 million of cash resources, down from CHF 91.4 million at December 31, 2025. The composition is conservative and liquid, although the company disclosed exposure to interest rates and foreign-exchange movements because treasury assets include U.S.-dollar and euro balances. The Q2 2026 Takeda milestone and Lilly amendment were announced after the quarter and therefore are separate from the March 31 resource figure.

R&D remains the dominant cost even after restructuring

This is an asset-light laboratory and clinical-development model in accounting terms: free cash flow is driven far more by R&D expense and milestone timing than by factories or heavy fixed assets. That helps flexibility, but it does not remove financing risk. If major programs require larger or longer trials before another partnership or milestone, burn could accelerate again.

What gives AC Immune a competitive advantage?

The platform-and-partner model creates several defensible resources

Active immunotherapy may offer a practical differentiation versus frequently infused monoclonal antibodies: patients generate their own polyclonal antibodies, potentially enabling durable responses and less frequent dosing. The hypothesis still requires clinical validation, but it is strategically coherent for prevention, where long treatment duration and health-system access matter. Morphomer compounds add a second route by targeting pathology inside cells, where antibodies have limited access.

Competition is program-specific and scientifically intense

AC Immune does not have a protected monopoly over Alzheimer’s or Parkinson’s biology. Its 20-F identifies direct competitors across vaccines, small molecules, and imaging. Approved monoclonal antibodies such as Leqembi and Kisunla also establish a therapeutic benchmark for efficacy, safety monitoring, and reimbursement. ACI-24 therefore must compete not only with other vaccines but also with established anti-amyloid treatment paradigms.

Who owns AC Immune, and how is it governed?

Ownership is concentrated, but voting rights are one-share-one-vote

The 2025 annual filing reported 101,773,573 common shares outstanding at March 1, 2026, and all common shares carried the same voting rights. Biotechnology Value Fund was the largest disclosed holder at 19.5%, followed by dievini at 16.0%, Varuma at 11.8%, and Affiris at 6.3%. Concentration can support long-duration biotechnology investment, because specialist and strategic holders may tolerate clinical timelines better than short-term owners. It can also give a small number of shareholders meaningful influence over director elections and capital strategy.

The CEO transition is a material governance variable

Co-founder Andrea Pfeifer retired from the CEO role after 23 years. Board Chair Martin Zügel became interim CEO while the board conducts a permanent search; Pfeifer moved to an advisory role and was designated Honorary Chair and Co-Chair of the Scientific Advisory Board. The leadership transition announcement matters because 2026 contains several program-defining milestones. Temporary concentration of chair and executive responsibilities can speed decisions, but succession quality and continuity of scientific leadership remain important watch items.

Which opportunities and risks could change the story?

The most important opportunities are evidence and partnering events

The highest-value opportunity is to convert suggestive biomarker signals into a credible registration path. Final ACI-7104 week-104 data could strengthen the case for disease modification in Parkinson’s disease and support regulatory discussions or a partnership. ACI-19764 Phase 1 results could validate a wholly owned oral small molecule with applications inside and potentially outside neurodegeneration. For ACI-24, stronger AD4 immunogenicity could improve Takeda’s option economics. The April 2026 Lilly amendment, including CHF 10.0 million upfront and more than CHF 1.7 billion of potential future milestones, shows that partner interest can create value before approval.

The risk side is equally company-specific. Small early trials may overstate efficacy; protocol changes can delay timelines; partners can terminate agreements; manufacturing and CRO dependencies can interrupt development; patents may not prevent design-arounds; and reimbursement may be difficult if prevention requires treating large populations for years. The company also disclosed that it has not completed a large pivotal trial, built commercial manufacturing, or operated a sales organization.

Why does AC Immune matter for valuation?

A conventional DCF built from current revenue and operating margin is not a useful primary method for AC Immune. Current contract revenue is episodic, operating cash flow is negative in normal development years, and no product has an approved commercial forecast. A better approach is a program-level risk-adjusted net present value model combined with net cash, expected collaboration cash flows, and corporate overhead.

The company’s June 2026 investor presentation reported more than CHF 400 million of upfront payments from deals and more than CHF 4.3 billion of possible future milestones. Those headline figures are not equivalent to present value: milestones are conditional, often years away, and may depend on partner discretion, trial success, approval, and sales thresholds. A rigorous model applies probabilities and discounts each payment at an appropriate biotechnology risk rate.

• Base operating inputs: quarterly R&D, G&A, cash resources, deferred revenue, and likely trial expansion costs.
• Program inputs: addressable population, treatment duration, pricing assumptions, probability of approval, launch timing, peak penetration, royalties, and milestone schedule.
• Sensitivity inputs: ACI-7104 clinical effect, ACI-24 formulation success, Takeda option exercise, ACI-19764 Phase 1 profile, and future financing terms.
• Terminal treatment: avoid a standard mature-company terminal growth formula until there is a credible commercial portfolio; use explicit patent- and royalty-life cash flows.